Expression of microRNA-590 in patients with chronic coronary heart disease, atrial fibrillation, and their combination
- Authors: Lerner D.D.1, Mayanskaya S.D.1, Kravtsova O.A.2, Tambovtseva R.S.2
-
Affiliations:
- Kazan State Medical University
- Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology
- Issue: Vol 104, No 1 (2023)
- Pages: 30-37
- Section: Theoretical and clinical medicine
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/91124
- DOI: https://doi.org/10.17816/KMJ91124
- ID: 91124
Cite item
Open Access
Access granted
Abstract
Background. The role of microRNAs in the processes of remodeling, proliferation, and fibrogenesis of myocardial cells is not clear enough.
Aim. Analysis of the microRNA-590 expression level in patients with chronic coronary heart disease, atrial fibrillation, as well as their combination to assess the potential prognostic significance of the expression level.
Material and methods. The study included 94 patients divided into three clinical groups: the first — with non-valvular atrial fibrillation without coronary heart disease (39 people); the second — with non-valvular atrial fibrillation and coronary heart disease (22 patients); the third — with ischemic heart disease without atrial fibrillation (23 patients). The comparison group consisted of 10 people without atrial fibrillation and coronary heart disease. Venous blood was taken from all subjects, from the plasma of which microRNA was isolated. The relative level of microRNA expression was estimated based on real-time polymerase chain reaction data obtained during the reaction on a cycler using commercial TaqMan probes and primers. The statistical significance of differences between groups was determined using one-way analysis of variance, followed by post-hoc analysis using Tukey's contrasts, differences were considered statistically significant at p <0.05. The Shapiro–Wilk test was used to assess the normality of the distribution of residuals.
Results. A statistically significant decrease in the expression level of microRNA-590 was registered in the third (p=0.0104) and in the second (p=0.0046) groups compared with the control group, as well as in patients with atrial fibrillation and left atrial dilatation (p=0.0313), with recurrent arrhythmias after radiofrequency ablation (p=0.0083) and with permanent atrial fibrillation (p=0.0242).
Conclusion. Ischemic heart disease, including when combined with atrial fibrillation, and aggravating factors, such as left atrial dilatation, permanent atrial fibrillation, recurrence of arrhythmia after radiofrequency ablation, lead to a decrease in the expression level of microRNA-590.
Full Text
About the authors
Dina D. Lerner
Kazan State Medical University
Author for correspondence.
Email: dinakaz84med@mail.ru
ORCID iD: 0000-0002-2123-7141
PhD Stud., Depart. of Hospital Therapy
Russian Federation, Kazan, RussiaSvetlana D. Mayanskaya
Kazan State Medical University
Email: Smayanskaya@mail.ru
ORCID iD: 0000-0001-6701-5395
M.D., D. Sci. (Med), Prof., Depart. of Hospital Therapy
Russian Federation, Kazan, RussiaOlga A. Kravtsova
Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology
Email: okravz@yandex.ru
ORCID iD: 0000-0002-4227-008X
Cand. Sci. (Biol.), Assoc. Prof., Depart. of Biochemistry, Biotechnology and Pharmacology
Russian Federation, Kazan, RussiaRegina S. Tambovtseva
Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology
Email: rustyamova.regina@mail.ru
ORCID iD: 0000-0002-0603-8849
Junior Researcher, IFMiB, Scientific and Clinical Center for Precision and Regenerative Medicine, Open Lab Genetic and Cell Technologies
Russian Federation, Kazan, RussiaReferences
- Wang F, Zhang H, Wang C. Mir-590-3p regulates cardiomyocyte P19CL6 proliferation, apoptosis and differentiation in vitro by targeting PTPN1 via JNK/STAT/Nf kB pathway. Int J Exp Pathol. 2020;101:196–202. doi: 10.1111/iep.12377.
- Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492(7429):376–381. doi: 10.1038/nature11739.
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. doi: 10.1016/j.cell.2006.07.024.
- Djuric U, Ellis J. Epigenetics of induced pluripotency, the seven-headed dragon. Stem Cell Res Ther. 2010;1(1):3. doi: 10.1186/scrt3.
- Al-Hasani K, Mathiyalagan P, El-Osta A. Epigenetics, cardiovascular disease, and cellular reprogramming. J Mol Cell Cardiol. 2019;128:129–133. doi: 10.1016/j.yjmcc.2019.01.019.
- Gilsbach R, Schwaderer M, Preissl S, Grüning BA, Kranzhöfer D, Schneider P, Nührenberg TG, Mulero-Navarro S, Weichenhan D, Braun C, Dreßen M, Jacobs AR, Lahm H, Doenst T, Backofen R, Krane M, Gelb BD, Hein L. Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo. Nat Commun. 2018;9(1):391. doi: 10.1038/s41467-017-02762-z.
- Lozano-Velasco E, Franco D, Aranega A, Daimi H. Genetics and epigenetics of atrial fibrillation. Int J Mol Sci. 2020;21(16):5717. doi: 10.3390/ijms21165717.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262.
- Li Y-D, Hong Y-F, Yusufuaji Y, Tang B, Zhou X, Xu G-J, Li J-X, Sun L, Zhang J-H, Xin Q, Xiong J, Ji Y, Zhang Y. Altered expression of hyperpolarization-activated cyclic nucleotide-gated channels and microRNA-1 and -133 in patients with age-associated atrial fibrillation. Mol Med Rep. 2015;12:3243–3248. doi: 10.3892/mmr.2015.3831.
- Della-Fazia MA, Castelli M, Piobbico D, Pieroni S, Servillo G. The Ins and Outs of HOPS/TMUB1 in biology and pathology. Febs J. 2021;288(9):2773–2783. doi: 10.1111/febs.15539.
- Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677–684. doi: 10.1161/CIRCRESAHA.109.215566.
- Ahlin F, Arfvidsson J, Vargas KG, Stojkovic S, Huber K, Wojta J. MicroRNAs as circulating biomarkers in acute coronary syndromes: A review. Vascul Pharmacol. 2016;81:15–21. doi: 10.1016/j.vph.2016.04.001.
- Piccoli MT, Gupta SK, Thum T. Noncoding RNAs as regulators of cardiomyocyte proliferation and death. J Mol Cell Cardiol. 2015;89(Pt A):59–67. doi: 10.1016/j.yjmcc.2015.02.002.
- He PP, OuYang XP, Li Y, Lv YC, Wang ZB, Yao F, Xie W, Tan YL, Li L, Zhang M, Lan G, Gong D, Cheng HP, Zhong HJ, Liu D, Huang C, Li ZX, Zheng XL, Yin WD, Tang CK. MicroRNA-590 inhibits lipoprotein lipase expression and prevents atherosclerosis in apoE knockout mice. PLoS One. 2015;10(9):e0138788. doi: 10.1371/journal.pone.0138788.
- Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B, Wang N, Li X, Feng T, Hong Y, Yang B. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res. 2009;83(3):465–472. doi: 10.1093/cvr/cvp130.
Supplementary files
